A randomized pharmacokinetic and pharmacodynamic trial of two regular human insulins demonstrates bioequivalence in type 1 diabetes and availability of biosimilar insulin may improve access to this medication.
Sérgio VencioRafael Caiado-VencioLeonardo Ferreira CaixetaMałgorzata MasierekWojciech MlynarskiJózef DrzewoskiJustin M GregoryPublished in: Diabetes, obesity & metabolism (2022)
The experimental product regular human insulin and comparator Humulin® R are bioequivalent in patients with T1DM. Wider entry to the pharmaceutical market of affordable, biosimilar regular insulins may substantially improve access to insulin for many socioeconomically disadvantaged patients with diabetes.